M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

Not Applicable

Recruiting

Conditions: Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Medical Chart Review
Other: Extension of Community Health (ECHO) Telementoring Clinic
Other: Questionnaire Administration
Other: In-Country Workshops
Other: Professional Oncology Educations Programs

First Posted Date: 2021-07-30

Last Posted Date: 2024-08-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 312

Registration Number: NCT04984551

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy

Phase 2

Recruiting

Conditions: Metastatic Malignant Neoplasm in the Liver
Primary Malignant Liver Neoplasm
Liver and Intrahepatic Bile Duct Neoplasm

Interventions: Other: Quality-of-Life Assessment
Procedure: Surgical Procedure

First Posted Date: 2021-07-29

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 140

Registration Number: NCT04982653

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

Phase 1

Completed

Conditions: Biochemically Recurrent Prostate Carcinoma
Localized Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Drug: Fluorine F 18 rhPSMA-7.3
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2021-07-27

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT04978675

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Phase 2

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Acalabrutinib
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Lenalidomide
Drug: Prednisone
Biological: Rituximab
Biological: Tafasitamab
Drug: Vincristine

First Posted Date: 2021-07-27

Last Posted Date: 2024-12-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04978584

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Recurrent Acute Biphenotypic Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Biphenotypic Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Decitabine and Cedazuridine
Drug: Venetoclax

First Posted Date: 2021-07-26

Last Posted Date: 2024-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04975919

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

Early Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Procedure: Fecal Microbiota Transplantation
Drug: Fecal Microbiota Transplantation Capsule
Other: Questionnaire Administration
Procedure: Resection
Procedure: Therapeutic Colonoscopy

First Posted Date: 2021-07-23

Last Posted Date: 2024-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT04975217

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Phase 1

Active, not recruiting

Conditions: Adenoid Cystic Carcinoma
Metastatic Adenoid Cystic Carcinoma

Interventions: Drug: AL101
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2021-07-22

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT04973683

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIC Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Bintrafusp Alfa
Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2021-07-21

Last Posted Date: 2023-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT04971187

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

Phase 2

Withdrawn

Conditions: Resectable Hepatocellular Carcinoma

Interventions: Biological: Nivolumab
Biological: Pegargiminase
Procedure: Resection

First Posted Date: 2021-07-16

Last Posted Date: 2023-02-16

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04965714

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Phase 2

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Unresectable Solid Neoplasm

Interventions: Biological: Nivolumab

First Posted Date: 2021-07-12

Last Posted Date: 2024-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04957615

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy